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tor (CAR)T cell therapies among the first to reach market. Although these therapies are currently manufactured using
patient-derived cells, therapies using healthy donor cells are in development, potentially offering avenues toward process
improvement and patient access. An allogeneic model could significantly reduce aggregate cost of goods (COGs), potentially
improving market penetration of these life-saving treatments. Furthermore, the shift toward offshore production may help
reduce manufacturing costs. In this article, we examine production costs of an allogeneic CAR-T cell process and the poten-
tial differential manufacturing costs between regions. Two offshore locations are compared with regions within the United
States. The critical findings of this article identify the COGs challenges facing manufacturing of allogeneic CAR-T immuno-
therapies, how these may evolve as production is sent offshore and the wider implication this trend could have.Key Words: cell therapy, chimeric antigen receptor, chimeric antigen receptorT cells, manufacturing, offshoring, production
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The recent approval by the U.S. Food and Drug
Administration (FDA) of the first chimeric antigen
receptor (CAR)T cell therapies [1,2] marks a sig-
nificant step toward the emergence of a new para-
digm in cancer treatment. Because these therapies
have only recently made their way out of investiga-
tional clinical trials, overall production volumes
remain small and many questions on reimbursement
have yet to be resolved [2]. Nevertheless, the robust
clinical pipeline of CAR-T cell therapies from a
number of developers coupled with the promise of
more approvals will create the need for scalable,
robust and cost-effective manufacturing and supply
chain models that do not compromise therapeutic
efficacy or patient safety [3].
To date, CAR-T cell therapies have largely been
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extracted, manipulated ex vivo and then re-infused.
Furthermore, CAR-T cell therapies have been manu-
factured in centralized facilities, with the patient’s
apheresis product being transported either fresh or
cryopreserved from the clinical facility to a
manufacturing facility and back. This mode of pro-
duction has been associated with high per-unit
manufacturing costs, leading many to seek ways of
containing key cost drivers, including ancillary materi-
als, transportation and logistics and skilled labor [4].
The primary aim of this article is to identify how
trends in the production of CAR-T cell therapies,
namely, the development of an allogeneic model reli-
ant upon donor cells, the geographic dispersion of
production and consumption and the decreasing
cost of ancillary materials, are likely to affect overall
cost of goods (COGs), thereby potentially facilitatingughborough University, Leicestershire, LE11 3TU, UK. E-mail:
y. Published by Elsevier Inc. This is an open access article under the CC BY
CAR-T cell therapy manufacturing 225greater market penetration of these new life-saving
treatments. A process economics modelling and cal-
culation tool is used to model how CAR-T cell ther-
apy production costs change in light of these trends.
The results of this study are significant beyond CAR-
T cell therapies because therapies developed on the
basis of other cell types will face similar challenges as
they reach market and seek ways to reduce
manufacturing costs.Current Manufacturing Strategies for CAR-T
Therapies
Today, cell and gene therapies follow one of two
main modes of production, which differ in regard to
the source of the cells used to manufacture these
therapeutic products. Autologous therapies involve
the extraction, manipulation and re-infusion or re-
administration of a patient’s own cells, whereas allo-
geneic therapies use previously extracted and banked
donor cells, making them more akin to an off-the-
shelf product. These two main modes of production
are used for therapies involving various cell types,
including T cells, natural killer (NK) cells and mes-
enchymal stromal cells.
This article focuses specifically on CAR-T cell
therapies due to their new arrival in the market and
acute need for a commercially sustainable
manufacturing and supply chain model. Current
manufacturing strategies for CAR-T therapiesFigure 1. High-level process overview representation of autologous and a
products as manufacturing starting material. However, it may be possible
processes, patient material will be evaluated to inform product selection
made-to-order. Manufacturing of product may take place at a centralizedinvolve harvesting T cells, which are subsequently
genetically modified and expanded ex vivo. This
expanded product is then re-infused back into the
patient from whence the cells first came. Harvesting
and re-infusion are currently carried out in a clinical
environment whereas manufacturing is conducted in
a specialized current Good Manufacturing Practices
(cGMP) facility [5].
It has been suggested that, given the logistical
challenges and shipping costs, decentralized
manufacturing of these therapies within the clinic or
hospital may be both feasible [4] and cost effective
[6,7]. Indeed, this proposal is attractive given the
role of the patients’ own material in the production
of these therapies. Nevertheless, commercial CAR-T
cell therapies such as Gilead’s Yescarta (axicabta-
gene ciloleucel) and Novartis’s Kymriah (tisagenle-
cleucel) are manufactured in large facilities located
in El Segundo, California (Yescarta) and in Morris
Plains, New Jersey, with additional manufacturing
capacity in Leipzig, Germany (Kymriah).
Centralized manufacturing is likely to persist in
the near term, given the difficulty of implementing
commercially compliant quality control (QC) and
quality assurance in multiple locations, as well as the
relative ease and efficacy with which the cells col-
lected by apheresis and the final CAR-T cell product
can be cryopreserved and thawed [8]. Even with allo-
geneic sourcing of cells, which may eliminate the
need for time-sensitive logistics to the manufacturingllogeneic CAR-T therapies. Current developers are using apheresis
to substitute this with a blood draw. For allogeneic manufacturing
, which may be shipped from a storage facility directly rather than
facility or a decentralized facility.
226 R.P. Harrison et al.site where cells are harvested and banked, centralized
manufacturing should be favored (Figure 1). Fur-
thermore, the development of an allogeneic model
enables the production of multiple doses from a sin-
gle source, facilitating greater economies of scale,
supporting production scale-up rather than scale-
out.Toward a Novel CAR-TManufacturing
Paradigm
Changes in the way that CAR-T cell therapies are
produced and delivered will have an impact on the
overall COG. With allogeneic production, many
doses are produced from each donor, lowering unit
costs considerably. Furthermore, we assume that the
growth of the cell and gene therapy market will mean
new entrants and greater competition, thereby lower-
ing the cost associated with producing ancillary
materials under cGMP, assuming no shortages (i.e.,
certain human-derived products).
The geography of production will continue to
evolve as a result of the dynamic relationship between
transportation and automation. On the one hand, the
stable nature of cellular products that can be cryopre-
served without significantly affecting potency and the
high rate of recovery upon thawing provide a potential
opportunity to relocate production ever further from
the end user. This will enable manufacturers to
explore alternative methods to control COGs  by
relocating production to low-cost locations  without
compromising quality. However, moving production
further afield, although technically feasible, will likely
lead to increased transportation costs and may intro-
duce delays at border crossings.
Furthermore, the cost savings associated with
shifting production offshore may be short-lived as an
increasing proportion of the production process is
automated. CAR-T cell therapy manufacturing has
become decidedly more automated with the develop-
ment and deployment of new equipment that encap-
sulates an increasingly diverse array of functions,
such as Miltenyi Biotec’s CliniMACS Prodigy Sys-
tem. By consolidating key processes, such as liquid
handling and some in-process manipulations, COG
values for academic dose production have been
quoted as low as $6000 [6] to $20 000 [7]. These
values do not, however, compare to similar costs
incurred by approved products because they lack
research and development costs, overheads, labor,
facility costs, QC and analytics, FDA monitoring,
licenses and royalties, clinical site onboarding, ship-
ping and logistics as well as the profit margin.
Despite advances in process automation, critical
steps in commercial cell therapy manufacturing,
including QC, quality assurance and analyticaltesting, still depend on human labor [9,10]. Further-
more, activities, such as research and development,
regulatory affairs, ongoing FDA-mandated monitor-
ing of gene-modified products (15 years), intellectual
property management, clinical site onboarding and
management and shipping and logistics, among
others, are difficult to automate.
The bespoke nature as well as the high cost and
complexity associated with the current manufacturing
model may limit market penetration and long-term
sustainability. For this reason, there are efforts under-
way to address the most significant cost and risk
drivers in the production of CAR-T cell therapies: sin-
gle dosing associated with the autologous model,
the production of qualified ancillary materials [11],
transporting cryopreserved materials across large
geographic distances [12] and hiring and retaining
skilled labor. These efforts affect each other and
the overall COGs associated with CAR-T cell therapy
manufacturing in complex ways, as the tradeoff
between offshore production and automation demon-
strates.Modelling a New CAR-TManufacturing
Paradigm
This article models how changes to the traditional
CAR-T cell therapy manufacturing paradigm are
likely to affect COGs. It considers how the develop-
ment of an allogeneic production model, the poten-
tial relocation of production to lower cost domestic
locations and offshore to other countries, as well as
the reduced cost of critical ancillary materials inter-
act with one another and, more broadly, shape
COGs as a whole.
The analysis uses a process economics modelling
and calculation tool developed to examine COGs for
production of advanced therapies [12,13]. The eligi-
ble patient market was calculated for the USA by
examining the number of patients with blood cancer
per year (171,000) [14], assuming that allogeneic
CAR-T therapies could capture 30% of this market
and further assuming that a new therapeutic provider
could capture 35% of this market. These values were
then applied proportionate to the population for all
of the countries in the modelling exercise with the
exception of China where a new therapeutic provider
was assumed to capture 5% of the domestic market.
A further breakdown of numbers can be located in
the supplementary information. Manufacturing
capacity required is calculated based on producing
approximately 18 000 to 60 000 doses/annum to
meet these patient numbers.
Labor calculations and employee numbers were
estimated following personal communications with
contract manufacturers. Facility and equipment are
CAR-T cell therapy manufacturing 227amortized over 10 years as suggested by the World-
wide Capital and Fixed Assets Guide [22]. Labor
and equipment have a 25%+/- margin for error on
idle capacity and use at any given time period over
the projected roll out period. Loan agreements are
assumed at 10 years, with 5% interest. An invest-
ment discount factor is not applied. Staffing costs are
calculated per salaried full-time individual at a given
band within the company. Administrative costs are
captured solely in the employment of administrative
staff and associated training, not through any other
costs or multipliers. Research and development
costs, licensing, royalties and sales costs are not cap-
tured by this model. A further breakdown of costs is
located in the supplementary information.
The manufacturing process examined here
involves the production of an allogeneic CAR-T cell
therapy manufactured in a central manufacturing
facility using healthy donor-derived material. The
benefit of choosing a healthy donor to a multiple-
patient therapeutic model rather than a patient-spe-
cific one is to study the simpler case before turning in
due course to the complexity of autologous supply
with increased costs [15,16].
Scalable cell-processing technologies have been
identified as a key factor in driving down the
manufacturing costs for cell therapies [17,18]. For
autologous CAR-T cell products, these platforms are
likely to be smaller scale and modular with isolated
product streams to separate out the batches and to
allow efficient line-clearance procedures [19]. For
allogeneic second-generation CAR-T products, the
number of patients able to receive the product is
higher and consequently the production scale will be
similarly larger.
While there are few regulatory hurdles associated
with moving production to lower cost locations
domestically, there are several challenges associated
with offshoring production. The movement of living
cells and tissues across borders is subject to scrutiny
on the part of national regulatory bodies such as the
FDA in the United States and requires international
harmonization of regulatory requirements to ensure
the fluid movement of intermediate and final goods.
Recent efforts by the International Standards Orga-
nization (ISO) to codify standards for cell transporta-
tion are likely to enable greater integration across
countries moving forward.
Similarly, a recent position paper by the FDA has
outlined alternative development pathways for
advanced therapies [20], permitting multiple manu-
facturers to produce biologics under the same proto-
col and then treat patients enrolled in clinical trials at
their individual sites. In this case, safety and efficacy
data are pooled from all sites, and submitted as part
of the biologics application for each individual site.This direction of travel highlights the recognition by
stakeholders that advanced therapies differ from tra-
ditional pharmaceuticals and thus require their own
set of flexible regulatory, oversight and control mech-
anisms.
To study the efficacy of offshore CAR-T cell
therapy manufacturing, we model the manufacturing
process in four distinct geographies: Cambridge,
Massachusetts (USA), Manchester, New Hampshire
(USA), Monterrey, Nuevo Leon (Mexico) and Bue-
nos Aires, Buenos Aires (Argentina). These geogra-
phies are selected to create variation in key variables,
such as labor cost, transportation cost and facility
cost, allowing us to understand how much of a cost
driver these factors are in cell therapy manufacturing.
These locations are not selected as final markets, but
as manufacturing locations for therapies to be com-
mercialized in the US market. They do not necessar-
ily represent existing cell therapy manufacturing
hubs, but their characteristics enable variance along
dimensions that support the article’s approach.
Given its strong biotechnology innovation ecosys-
tem and focus on biomanufacturing, Cambridge
serves as a case study representing onshore produc-
tion. Manchester serves as a lower cost location with
a significant role in the regenerative medicine indus-
try given the newly established Advanced Regenera-
tive Manufacturing Institute (ARMI). Monterrey’s
strong industrial base and engineering talent, prox-
imity to the US market and harmonization on trade
make it a viable low-cost nearshoring destination.
The final case study is Buenos Aires, which serves as
a viable offshore location because of its biomanufac-
turing base and lower cost of labor. We make a series
of critical assumptions in our modelling exercise: we
assume that these four locations have sufficiently
large pools of skilled labor that vary primarily in
regard to average wages, and that they all have quali-
fied space for biomanufacturing that vary only in
regard to price. By selecting onshore, nearshore and
offshore cases, we include a number of variables,
including cost of labor, cost of qualified space and
cost of transportation and logistics for inbound and
outbound clinical products. A process flow diagram
outlining the hypothetical manufacturing strategy
described is presented in Figure 2.Results and Discussion
Manufacturing strategies for CAR-T cell therapies
are still in their infancy and undergoing rapid
change. Historically, cell-manufacturing platforms
have been developed using technology adapted from
biopharmaceutical production. Consequently, there
has been significant room for further optimization
and improvement, which are only beginning to be
Figure 2. Process flow diagram for manufacturing of allogeneic CAR-T cellular therapies. Items in the dotted-line box are obtained from
inventory rather than produced routinely as part of the process. Transport steps are highlighted (red asterisk); inbound clinical products are
modelled as originating in the USA with outbound clinical products scheduled for delivery to clinical locations in each country.
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CAR-T cell therapy manufacturing 229fully exploited. Looking forward, we are likely to wit-
ness significant improvements in reproducibility and
replicability of manufacturing platforms as well as
improvements in scale-up technologies for allogeneic
products and scaled-down separate production
streams for autologous. In this section, we present
the results of the modelling exercise, and discuss
implications of this work for cell therapies and regen-
erative medicine more broadly.Autologous versus allogeneic
Autologous CAR-T therapy has several advantages
over allogeneic in its mechanistic approach to treat-
ment. Autologous products taken from the patient’s
own cells possess the ability to re-engraft within the
host and persist long term, providing a durable
response. Although this effect is likely to be absent
from allogeneic approaches that use master banks of
donor leukocytes, there are significant COG reduc-
tion advantages to be gained with deriving multiple
therapeutic doses from a single manufactured batch
(Figure 3). This COG reduction stems chiefly from
the ability to spread the high initial cost of the donor
materials and subsequent selection and enrichment,
as well as the associated batch QC across a larger
number of doses.Staff and site costs
Two of the key cost drivers underlying operating
expenses for manufacturing cell and gene therapies
are staff and facility costs. Offshoring presents
opportunities to reduce these operating expenses
both through direct reductions in the workforce pay-
roll, and also through reduced site costs fromFigure 3. COGs between autologous and allogeneic CAR-T cell manufa
(allo) day manufacturing process with an identical facility structure and Q
present for the autologus process. Percentages shown as portion of total pcheaper office space and facilities management. Staff
and site costs were modelled for the four regions
(Figure 4). Significant reductions in staff costs were
demonstrated for Monterrey, Mexico (4.34 million
US$ per year (M$/y) and Buenos Aires, Argentina
(4.57 M$/y) versus the two USA-based regions
Cambridge (17.53 M$/y) and Manchester (12.26 M
$/y). Potential reductions on site costs were signifi-
cantly less with Mexico (2.95 M$/y) and Argentina
(2.83 M$/y) versus Cambridge (3.3 M$/y) and Man-
chester (3.2 M$/y).Consumable costs
Although site and staff costs are significant monetary
expenditures on aggregate, these costs are relatively
minor contributors to the final headline figure dose
cost. Indeed, under the manufacturing scenario
examined, consumables account for a far higher pro-
portion of dose cost than site and staff costs
(Figure 5A). Indeed, the cost of consumables
increases as a therapy makes its way through the clin-
ical pipeline and regulators begin to demand that
manufacturers shift from research-grade to cGMP
consumables. It is yet unclear how the cost of con-
sumables will change as the industry matures. While
we may see economies of scale-driven cost reduc-
tions with increased approvals, they will likely not
lead to lower prices without increased competition in
the supply base.
The sensitivity analysis (Figure 5B) presents
increasing and decreasing material COGs relative to
current prices and highlights the significance of these
potential reductions or increases in consumable
COGs to the final unit price. Furthermore, these
reductions would elevate the importance of staffcturing processes. The process modelled used an 8- (auto) and 10-
C panel. Staffing levels were similar but additional operators were
roduction COGs.
Figure 4. Staff (A) and site (B) costs between regions. Employment numbers remain constant between regions. Wage metrics were adjusted
using local wage indeces. Percentages shown as portion of total operating costs per year.
230 R.P. Harrison et al.costs (and to a lesser extent facility costs) as contrib-
utors to the final unit price. With reductions of
8090% on consumable COGs, staff costs increase
four-fold in their contribution to unit cost at »20%
of the total in Cambridge. This makes the potential
cost savings to be obtained through offshoring dra-
matically more appealing, at least temporarily. The
reduction in the weight of consumables on aggregate
COGs and increased weight of staff and facility cost
would strengthen the business case for greater auto-
mation in the production process while simulta-
neously eroding the business case for offshoring.Ramping up production
A phased roll-out of an allogeneic CAR-T cell ther-
apy is presented in Figure 6. This examines a theo-
retical cash flow, doses shipped and average COGs/
dose over a 10-year duration. Notably, research and
development costs as well as any licensing fees and
royalty costs are excluded from the cash flow, which
could significantly influence the upfront costs prior
to “year 0”. As the roll-out progresses to new mar-
kets and doses shipped increases, there is a marginal
but statistically significant decrease in COGs/dose.More significantly, it is important to note that the
COGs between sites converges as roll-out progresses
(minimum/maximum Tukey plots). This suggests
that, as the product landscape matures, the differ-
ence in production costs between regions will
become less apparent.Conclusions and Future Outlook
Despite the evident challenges associated with trans-
ferring even simple processes between multiple sites
[21], standardized production facilities and associated
quality systems have been established by both cell and
gene therapy developers and contract manufacturing
organizations across continents. Similarly, solutions
such as Thermofisher’s CryoHubs, World Courier’s
Logistics Platform and the Trakcell and Vineti orches-
tration platforms are helping to establish robust sup-
ply chains to support the movement of goods.
Investment has also taken place within the clinic itself,
particularly in the UK with the establishing of
Advanced Therapy Treatment Centers at distributed
clinical locations to create seamless supply chains
from harvest to release of cell products [4]. These key
Figure 5. Breakdown of cost per dose shipped between regions (A) and a sensitivity analysis of changing consumable costs (B). The sensitiv-
ity analysis (B) examines percentage cost increases or reductions to material COGs. The X-axis examines progressive COGs reductions in all
consumable materials used in the process from 100% (current prices) up to 150% (equivalent to a 50% increase on current prices) and down
to 50% (equivalent to a 50% discount on current prices). At this 50% discount, transport becomes the largest contributor to cost of goods
and staff moves from being 11% of dose cost to 25% (in Cambridge, Massachusetts), significantly increasing its relative percentage contribu-
tion to final dose price. These figures do not include any potential savings realized through increasing economies of scale as doses shipped
across the advanced therapy industry increase. Unforeseen challenges such as customs barriers, which might affect inbound raw materials,
including virus to offshore sites, are not captured. QC, patient qualification tests and release testing are not included in these costs. Percen-
tages shown as portion of total production COGs per dose unit.
CAR-T cell therapy manufacturing 231developments minimize variation and help ensure
reproducibility across the value chain.
Although the systems are in place to facilitate off-
shoring, the burden of risk and associated unknownsmake the prospect unappealing at present given the
small current potential savings in operating costs ver-
sus additional complexity in operations manage-
ment. Furthermore, the trend toward greater process
Figure 6. Examining the progressive global roll-out of an allogeneic CAR-T therapeutic. The COGs/dose is presented as an average of all
four sites (Boston, USA, Manchester, USA, Monterrey, Mexico and Buenos Aires, Argentina). COGs ranges between $4280 and $3990
with a lower standard deviation between the costs of manufacturing site locations as roll-out progresses. No reductions in consumable costs
or shipping costs over time are accounted for. Box plots are presented as minimum/maximum Tukey plots.
232 R.P. Harrison et al.automation may eventually erode any marginal bene-
fit associated with lower labor costs in offshore loca-
tions. Finally, the commercial manufacturing model
for cell and gene therapies may require the creation
of more contained production systems. In the auto-
motive industry, the difficulty of transporting the
final product encourages companies to assemble cars
where they sell them, although many components
and subsystems may still be imported.
Cell and gene therapy manufacturing may even-
tually adopt a similar model, albeit for different rea-
sons. Here the cross-border movement of cells
creates a series of regulatory and cost-related chal-
lenges. For example, clearing customs is a non-trivial
task, especially when shipping personalized and per-
ishable treatments. Finally, large and dynamic mar-
kets protected by strong industrial policy regimes
may require domestic manufacturing to foster the
development of a novel industry within their political
economy.
This study has analyzed key forecasted trends
in the production of CAR-T cell therapies, and
how these trends are likely to shape production
costs, thereby affecting the degree to which these
therapies become commercial successes. Specifi-
cally, we have highlighted an allogeneic modelreliant upon donor cells, showing how the geo-
graphic dispersion of production and consumption
and the decreasing cost of ancillary materials are
likely to affect one another and further shape over-
all COGs. The modelling exercise and findings
presented here have implications for other cell and
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